Order Article Reprints

Porter RF, Szczesniak A-M, Toguri JT, Gebremeskel S, Johnston B, Lehmann C, Fingerle J, Rothenhäusler B, Perret C, Rogers-Evans M, et al. Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis. Molecules. 2019; 24(18):3338. https://doi.org/10.3390/molecules24183338

Porter, Richard Frederick, Anna-Maria Szczesniak, James Thomas Toguri, Simon Gebremeskel, Brent Johnston, Christian Lehmann, Jürgen Fingerle, Benno Rothenhäusler, Camille Perret, Mark Rogers-Evans, and et al. 2019. "Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis" Molecules 24, no. 18: 3338. https://doi.org/10.3390/molecules24183338

Porter, R. F., Szczesniak, A.-M., Toguri, J. T., Gebremeskel, S., Johnston, B., Lehmann, C., Fingerle, J., Rothenhäusler, B., Perret, C., Rogers-Evans, M., Kimbara, A., Nettekoven, M., Guba, W., Grether, U., Ullmer, C., & Kelly, M. E. M. (2019). Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis. Molecules, 24(18), 3338. https://doi.org/10.3390/molecules24183338